In this regard, research focused on the identification of aggregated tau as a useful biomarker [11] has paved the way to novel therapeutic strategies for Alzheimer’s disease based on the inhibition of tau aggregation [12]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.